The kynurenine pathway; A new target for treating maternal features of preeclampsia?

Research output: Contribution to journalReview articlepeer-review


In preeclampsia, vasospasm, oxidative stress, endothelial dysfunction, and immune dysregulation are key mediators of maternal disease. A new time-of-disease treatment is needed with the potential to treat these areas of pathophysiology. A review of the literature has indicated that metabolites of the kynurenine pathway have the potential to; (i) induce vasorelaxation of resistance arteries and reduce blood pressure; (ii) exert antioxidant effects and reduce the effects of poly-ADP ribose polymerase activation (iii) prevent endothelial dysfunction and promote endothelial nitric oxide production; (iv) cause T cell differentiation into tolerogenic regulatory T cells and induce apoptosis of pro-inflammatory Th1 cells. This has led to the hypothesis that increasing Kynurenine pathway activity may offer a new treatment strategy for preeclampsia.
Original languageEnglish
Pages (from-to)44-49
Early online date1 May 2019
Publication statusPublished - 1 May 2019


  • Immunoregulation
  • Kynurenine pathway
  • Preeclampsia
  • Vascular dysfunction


Dive into the research topics of 'The kynurenine pathway; A new target for treating maternal features of preeclampsia?'. Together they form a unique fingerprint.

Cite this